Ramucirumab biosimilar (Suzhou AlphaMab)

雷莫芦单抗生物类似药（莫芦单抗生物仿制药（苏州康宁杰瑞生物科技））

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRamucirumab biosimilar (Suzhou AlphaMab)
Drug Alias Name莫芦单抗生物仿制药（苏州康宁杰瑞生物科技）
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSuzhou Alphamab Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Alphamab Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeL01XC21
Related LinksN/A